Prevalence (expressed as column percentage in the table) of different non-organ-specific autoantibodies (NOSAs) within the population studied in relation to the presence of chronic liver disease (CLD)
| Anti-HCV positive (n=226) | Case controls (n=226) | HbsAg positive (n=87) | |
|---|---|---|---|
| NOSA positive (total) | 57 (25)3-150 | 14 (6) | 6 (7) |
| With CLD | 31 (14)3-150 | 4 (1.8) | 2 (2.3) |
| ANA positive (total) | 36 (16)3-150 | 8 (3.5) | 2 (2.3) |
| With CLD | 14 (6.2)3-150 | 3 (1.3) | 1 (1.1) |
| SMA positive (total) | 22 (10)3-150 | 6 (2.6) | 4 (4.6) |
| With CLD | 11 (5)3-150 | 1 (0.4) | 1 (1.1) |
| LKM1 positive (total) | 3 (1.3)3-150 | 0 (0) | 0 (0) |
| With CLD | 3 (1.3)3-150 | 0 (0) | 0 (0) |
| ANA + SMA positive (total) | 5 (2.2)3-150 | 0 (0) | 0 (0) |
| With CLD | 0 (0) | 0 (0) | 0 (0) |
| AMA positive (total)3-150 | 1 (0.4)3-150 | 0 (0) | 0 (0) |
| With CLD | 1 (0.4)3-150 | 0 (0) |
Values in parentheses are percentages.
↵3-150 p<0.05 v other groups.
ANA, anti-nuclear antibodies; SMA, anti-smooth muscle antibodies; LKM, anti-liver/kidney microsomes type 1 antibodies; AMA, anti-mitochondrial antibodies.